Birchview Capital, LP

BURLINGTON, VT · Quarter end: Sep 30, 2026 · Filed with SEC: Nov 13, 2026 · Open the SEC source ↗
Portfolio Return (1Y)——
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.$173.1M2026 Q3
Positions79
Top-10 ConcentrationPercent of the portfolio in the 10 largest holdings. High means the fund is concentrated in few stocks.56.0%

Birchview Capital, LP reported 79 positions worth $173.1M as of September 30, 2026 (13F filed November 13, 2026). Largest holding: KLAC (18.8%). Biggest move: new buy RARE ($5.6M).

10 / 79 positions shown
#SymbolCompanyValue ↓% Port.Shares1YYTDSince reported
▸ 1 KLACKla$32.5M18.80%166,938——-26.1%
▸ 2 BMYBristol Myers Squibb$14.0M8.08%224,245——+0.8%
▸ 3 LRCXLam Research$9.9M5.69%30,000——-35.8%
▸ 4BiodesixBiodesix$8.6M4.94%286,804———
▸ 5 CORTCorcept Therapeutics$6.4M3.67%55,200——-39.9%
▸ 6 OVVOvintiv$6.2M3.59%107,500——+12.2%
▸ 7 RAREUltragenyx Pharmaceutical$5.6M3.24%373,671——+5.8%
▸ 8 SLDBSolid Biosciences$5.2M2.99%715,955——-5.4%
▸ 9 PTGXProtagonist Therapeutics$4.9M2.85%35,000——-11.4%
▸ 10 PRTAProthena Corp Public$3.8M2.17%449,019——-4.9%

Pro Feature

The remaining 69 positions with Pro.

Upgrade to Pro

Read the 2026-Q2 quarterly report · 13F Filing Calendar

🔔 Tell me when this fund files a new 13F

No account needed: in your inbox the morning it is published.

Frequently Asked Questions

What stocks does Birchview Capital, LP hold as of Q3 2026?

Birchview Capital, LP reported 79 positions worth $173.1M in its Q3 2026 13F filing. Largest positions: KLAC (18.8%), BMY (8.1%), LRCX (5.7%), BIODESIX INC (4.9%) and CORT (3.7%).

What did Birchview Capital, LP buy in Q3 2026?

New positions: RARE, CONTINEUM THERAPEUTICS INC (CTNM) P @ 15.0 01/15/2027, IRLA, VALN and ANNEXON INC (ANNX) P @ 5.0 01/15/2027 (23 in all). Added to: DFTX, XENE, BBIO, ADAGENE INC and VYGR (13 in all).

What did Birchview Capital, LP sell in Q3 2026?

Reduced: BMY, PACB, KLAC, NKTR and LRCX (22 in all). Sold out entirely: VERA, QURE, BIOA, GPCR and NVO (16 in all).

13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.